Candel Therapeutics, Inc. (CADL)

9,97 -0,86 (-7,94%) Alla chiusura: 04:00PM EDT

Candel Therapeutics, Inc.

117 Kendrick Street
Suite 450
Needham, MA 02494
United States
617 916 5445
https://www.candeltx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 42

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.	President, CEO & Director	1,12M	N/D	1961
Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D.	Founder & Director	35k	N/D	1959
Dr. Francesca Barone M.D., Ph.D.	Chief Scientific Officer	506,76k	N/D	1978
Mr. Charles Schoch	Interim CFO, VP of Finance & Corporate Controller	N/D	N/D	1985
Dr. Seshu Tyagarajan Ph.D.	Chief Technical & Development Officer	335,27k	N/D	1968
Ms. Ileen B. Winick	Chief People Officer	N/D	N/D	N/D
Ms. Susan Stewart J.D., L.L.M.	Chief Regulatory Officer	N/D	N/D	1961
Dr. William Garrett Nichols M.D., M.S.	Chief Medical Officer	N/D	N/D	1969

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Candel Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.